Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDEFINE 2: CagriSema vs placebo in overweight/obesity with type 2 diabetes
jRCT2031220671Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2023
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial in Overweight, obesity and type 2 diabetes mellitus (T2DM) comparing CagriSema arm with Placebo arm (2 arms). Primary endpoints: Relative change in body weight and Achievement of >5% weight reduction. Started Mar 2023; status: completed.
02
Drugs
CagriSema
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031220671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220671.